Table 2 All Adverse and Serious Adverse Events

From: Autologous HIV-specific T cell therapy targeting conserved epitopes is well-tolerated in six adults with HIV: an open-label, single-arm phase 1 study

 

Adverse

Event (n = 20)

Duration (Days)

Relationship to

Infusion Product

Grade 1 (Mild)

General Malaise

1

Not related

Drowsiness

6

Not related

Heart Racing

1

Possible

Constipation

3

Possible

Dry Cough

2

Possible

Ingrown Hair

2

Not related

Warmth

1

Possible

Diaphoresis

0

Possible

Loss of Smell

12

Not related

Loss of Taste

12

Not related

Headache

0

Possible

Anxiety

296

Not related

Fatigue

21

Possible

Fatigue

23

Not related

Fatigue

1

Unlikely

Elevated Creatinine Serum

63

Not related

Grade 2 (Moderate)

Headache

0

Unlikely

Headache

0

Possible

Grade 3 (Serious)

COVID-19

Diseasea

7

Not related

Suicide Attempta

9

Not related

  1. aGrade 3 events required inpatient hospitalizations.
  2. A zero indicates the start and end date of symptom were the same. The relationship between the infusion product and the adverse event (AE) was based on occurrence relative to infusion, plausible biological mechanism for the infusion to cause the AE, participant status/health, and reoccurrence of AE.